Yıl: 2003 Cilt: 11 Sayı: supp3 Sayfa Aralığı: 21 - 37 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Duygudurum dengeleyicileri nedir?

Öz:
İki uçlu duygudurum bozukluğu yaygın bir hastalıktır. Kronik, yaşam boyu süren ve tekrarlayıcı bir hastalık olduğu için toplumsal maliyeti yüksektir. Tüm tekrarlayan hastalıklarda olduğu gibi akut episodların tedavisinin yanı sıra yeni episodları önlemeye yönelik koruyucu bir tedavi gereklidir. Duygudurum dengeleyicileri, iki uçlu bozulduğu olan hastalarda manik, hipo-manik, depresif ya da karma episodların şiddetini ve/veya sıklığını azaltırken başka bir duygudurum episoduna da kaymaya neden olmayan ajanlar olarak tanımlanabilir. Lityum, antipsikotikler, karbamazepin, valproat, lamotrijin, gabapentin ve topiramat gibi yeni antikonvulsanlar, kalsiyum kanal blokerleri ve elektrokonvulsif terapi bugün kullandığımız duygudurum dengeleyicileridir.
Anahtar Kelime: bipolar bozukluk psikoterapi lityum antipsikotikler antikonvulsanlar duygudurum düzenleyici psikofarmakoloji

Konular: Psikiyatri

-

Öz:
Bipolar disorder has a high prevalance. Being a chronic, life long and recurrent disorder it has a high burden on the community. Like in other recurrent disorders, not only acute treatment of the episodes but also prophylaxis is necessary. Mood stabilizers are defined as agents that decrease the intensity and/or frequency of manic, hypomanic, depressive or mixed episodes in clients with bipolar disorder without causing a switch to a different mood episode. Lithium, antipsychotics, carbamazepine, valproate, novel anticonvulsants like lamotrigine, gabapentine, topiramate, and calcium channel blockers and electroconvulsive therapy are currently accepted mood stabilizers.
Anahtar Kelime: mood stabilizer psychopharmacology bipolar disorder psychotherapy lithium antipsychotics anticonvulsants

Konular: Psikiyatri
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1.Abou-Saleh MX, Coppen AJ. Acute treatmant, long-term management, and prophylaxis of affective disorders. Psychiatric Annals 1987:17:301-308:
  • 2.Steiner M, Yonkers KA, Eriksson E. Mood Disorders in Women. Londra; Martin Dunitz; 2000.
  • 3.Leibenluft E. Women with bipolar illness: clinical and research issues. Am J Psychiatry 1996; 153:163-73.
  • 4.Akiskal HS. Mood Disorders: Introduction and Overview. Sadock BJ, Sadock VA, editörler. Kaplan & Sadock's Comprehensive Textbook of Psychiatry içinde. 7. Baskı. Philadelphia: liippincott Williams and Wilkins; 2000; s.1284-98.
  • 5.Horrow M, Goldberg JF, Grosman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990;47:665-671
  • 6.Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis 1993;181:238-245.
  • 7.Goodwin FK, Jamison KR. Manic Depressive Illness. New York; Oxford University Press; 1990.
  • 8.Goodwin GM. Prophylaxis of bipolar disorder: how and who should we treat in the long term? European Neuropsychophar-macology 1999;9(Suppl 4): 125-129.
  • 9.Prien RF, Potter WZ. NIMH Workshop Report on Treatment of Bipolar Disorder. Psychopharmacol Bull 1990;26:409-427.
  • 10.Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995:152:1635-1640.
  • 11.Oral T. Bipolar bozuklukta koruyucu sağaltım: Hangi hastalara, ne zaman? 3P Dergisi 2000;8(Ek 2):5-8.
  • 12.Tunca Z, Özerdem A, Kaya N. Koruyucu sağaltıma alınan hastaların izlenmesinde uygulamalar. 3P Dergisi 2000;8(Ek 2):9-18.
  • 13.Angst J. Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry 1996;30:61-71.
  • 14.Mendlewicz J, Souery D, Rivelli SK. Short-term and long-term treatment for bipolar patients: beyond the guidelines. J Affect Dis 1999:55:79-85.
  • 15.Baastrup PC, Schou M. Lithium as a prophylactic agent. Arch Gen Psychiatry 1967;16:162-172.
  • 16.Angst J, Weis P, Grof P. Lithium prophylaxis in recurrent affective disorders. BrJ Psychiatry 1970;116:604.
  • 17.Oral T. Duygudurum Düzenleyicileri. Klinik Psikofarmakoloji Bülteni 1999:9:1:14-20.
  • 18.Bowden CL. New concepts in mood stabilization. Neuropsychopharmacology 1998;19:194-199.
  • 19.Montgomery S, Van Zwieten B. ECNP Consensus Meeting March 2000 Nice. Guidelines for Investigating Efficacy in Bipolar Disorder. European Neuropsychopharmacology 2001:11:79-88.
  • 20.Frances Aj, Kahn DA, Carpenter D, Docherty JP, Donovan S. The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1998;59 (suppl 4):73-79.
  • 21.Frances A, Docherty JP, Kahu DA. The Expert Consensus Guidelines series. Treatment of bipolar disorder. J Clin Psychiatry 1996;57 (suppl 12A):l-88.
  • 22.Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ. Clinical practice guidelines for bipolar disorder from the department of Veterans Affair. J Clin Psychiatry 1998;60;1:9-21.
  • 23.Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 2000;61 (suppl 9):5-15.
  • 24.Cade J. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949:14:349-352.
  • 25.Scares JC, Gershon S. The psychopharmacologic specificity of the lithium ion: origins and trajectory. J Clin Psychiatry 2000;61 (suppl 9): 16-22.
  • 26.Greist JH. Current and potential uses of lithium. J Clin Psychiatry 1990;51(9):392-400
  • 27.Jefferson JW. Lithium. Sadock BJ, Sadock VA, editörler. Kaplan & Sadock's Comprehensive Textbook of Psychiatry içinde. 7. Baskı. Philadelphia: Lippincott Williams and Wilkins; 2000; s.2377-2390.
  • 28.Baldessarini RJ, Tondo L: Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview. Clin Drug Invest 1998; 15:337-351
  • 29.Mendlewicz J: Lithium discontinuation in bipolar illness: a double blind prospective controlled study. In Current trends in lithium and rubidium therapy. Edited by Corsini GU. Lancaster, England, Boston, MTP Press, 1984
  • 30.Tunalı D. Lityum endikasyonlan.Yazıcı O. (Ed) Duygudurum Bozuklukları-I içinde. Format matbbacılık, 1998, Istan-bul:s.93-107.
  • 31.Solomon DA, Ristow WR, Keller MB, Kane JM, Gelenberg AJ, Rosenbaum JF, Warshaw MG. Serum lithium levels and psychosocial function in patients with bipolar I disorder. Am J Psychiatry 1996; 153:1301-1307.
  • 32.Gerner RH, Stanton A. Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? J Clin Psychopharmacol 1992;12:57-63.
  • 33.Chou JC. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991; 11:3-21.
  • 34.Vahip S. iki uçlu duygudurum bozukluğunda depresif episod sağaltımı. 3P Dergisi 2000;8 (Ek 3):13-19.
  • 35.Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000;61 (suppl 9):35-40.
  • 36.Okuma T, Inanaga K, Otsuki S, Sarai K, Takashi R, Hazama H, Mori A, Watanabe M. A preliminary double-blind study of the efficacay of Carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berlin) 1981;73:95-96.
  • 37.Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204.
  • 38.Placidi OF, Lenzi A, Lazzerini F, Cassano GB, Akiskal MS. The comparative efficacay and safety of Carbamazepine versus lithium: a randomized double-blind 3 year trial in 83 patients. J Clin Psychiatry 1986;47:490-494.
  • 39.Wutkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM. The effect of Carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987;150:180-182.
  • 40.Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to Carbamazepine. Psychiatry Res 1987;21:71-83.
  • 41.Zarate C, Tohen M. Carbamazepine. Sadock BJ, Sadock VA, editörler. Kaplan & Sadock's Comprehensive Textbook of Psychiatry içinde. 7. Baskı. Philadelphia: Lippincott Williams and Wilkins; 2000; s.2283-2288.
  • 42.Emrich HM. Akut manide okskarbazepin ile yapılan çalışmalar. Int Clin Psychopharmacol 1990;5 (suppl l):83-88.
  • 43.McElroy SL, Harrison GP, Keck PE. Valproate. Sadock BJ, Sadock VA, editörler. Kaplan & Sadock's Comprehensive Textbook of Psychiatry içinde. 7. Baskı, Philadelphia: Lippincott Williams and Wilkins; 2000; s.2289-2299.
  • 44.Lambert PA, Carraz G, Borselli S, Carrel MS. Action neuropsychotrope d'unnouvel anti-epileptique: Le deepamide. Ann MedPsychol 1966;1:707-710.
  • 45.Oral ET, Karadğ F, Verimli A, Aran F, Adanur Aİ. Akut manide valproat. I. Biyolojik Psikiyatri Kongresi, Bursa, 1996.
  • 46.Brown R. US experience with valproate in manic-depressive illness: a multi-central trial. J Clin Psychiatry 1989;50 (suppl 3):25-30.
  • 47.Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PC, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD, for the Depakote Mania Study Group. Efficacy of divalproex vs lithium, placebo in the treatment of mania. JAMA 1994;271:918-924.
  • 48.McElroy SL, Keck PE, Stanton SP, Tuğrul KC, Bennett JA, Strakowski SM.A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatryl996;57:142-146.
  • 49.Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Anı J Psychiatry 1990;147:431-434.
  • 50.Sachs G. Is divalproex sodium an appropriate initial treatment for bipolar depression? Psychiatr Ann 1996;26 (suppl ):471.
  • 51.Lambert PA, Venaud G. Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nerv J Psychiatry 1995;7:1.
  • 52.Janicak PG, Newman RH, Davis JM. Advances in the treatment of mania and related disorders: a reappraisal. Psychiatr Ann 1992; 22(2) :92-103.
  • 53.Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck PE, Rhodes L, Bolden-Watson C, Zhou J, Asher JA. Spectrum of activity of lamotrigine in treatment refractory bipolar disorders. Am J Psychiatry 1999;156:1019-1023.
  • 54.Sussman N. Other anticonvulsants. Sadock BJ, Sadock VA, editörler. Kaplan & Sadock's Comprehensive Textbook of Psychiatry içinde. 7. Baskı. Philadelphia: Lippincott Williams and Wilkins; 2000; s.2299-2304.
  • 55.Zerjav-Lacombe S, Tabarsi E. Lamotrigine: a review of clinical studies in bipolar disorders. Can J Psychiatry 2001;46:328-333.
  • 56.Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Research 1997;72:145-148.
  • 57.Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD, for the Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
  • 58.Sporn J, Sachs G. The anticovulsant lamotrigine in treatment resistant manic depressive illness. J Clin Psychopharmacol 1997;17:185-189.
  • 59.Bowden CL, Calabrese JR, McElroy SL, Rhodes LJ, Keck PE, Cookson J. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999;45:953-958.
  • 60.Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851-853.
  • 61.Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000;61:638-642.
  • 62.Post RM, Frye MA, Leverich GS, Denicoff KD. The role of complex combination therapy in the treatment of refractory bipolar illness. CNS Spectrums 1998;5 (3):66-86.
  • 63.Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.Am J Psychiatry 1999; 156: 1164-1169.
  • 64.Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995;56:108-112.
  • 65.Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry I995;56: 411-417.
  • 66.Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY. Clozapine for treatment-refractory mania.Am J Psychiatry 1996;153:759-764.
  • 67.Tohen M, Jacobs.TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Saner T, Rlsser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A, Olanzapine HGGW Çalışma Grubu. Olanzapinin akut bipolar manideki etkinliği: çift-kör plasebo kontrollü çalışma. Arch Gen Psychiatry 2000;57:841-849.
  • 68.Parker G, Malhi G. Are atypical antipsycotic drugs also atypical antidepressants? Aust N Z J Psychiatry 2001;35:631-638.
  • 69.Andrade C, Gangadhar BN, Channabasavanna SM. Mania associated with electroconvulsive therapy. J Clin Psychiatry 1987;48:303-304.
APA Polat A, ÖNDER M (2003). Duygudurum dengeleyicileri nedir?. , 21 - 37.
Chicago Polat Aslıhan,ÖNDER M.Emin Duygudurum dengeleyicileri nedir?. (2003): 21 - 37.
MLA Polat Aslıhan,ÖNDER M.Emin Duygudurum dengeleyicileri nedir?. , 2003, ss.21 - 37.
AMA Polat A,ÖNDER M Duygudurum dengeleyicileri nedir?. . 2003; 21 - 37.
Vancouver Polat A,ÖNDER M Duygudurum dengeleyicileri nedir?. . 2003; 21 - 37.
IEEE Polat A,ÖNDER M "Duygudurum dengeleyicileri nedir?." , ss.21 - 37, 2003.
ISNAD Polat, Aslıhan - ÖNDER, M.Emin. "Duygudurum dengeleyicileri nedir?". (2003), 21-37.
APA Polat A, ÖNDER M (2003). Duygudurum dengeleyicileri nedir?. 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi, 11(supp3), 21 - 37.
Chicago Polat Aslıhan,ÖNDER M.Emin Duygudurum dengeleyicileri nedir?. 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi 11, no.supp3 (2003): 21 - 37.
MLA Polat Aslıhan,ÖNDER M.Emin Duygudurum dengeleyicileri nedir?. 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi, vol.11, no.supp3, 2003, ss.21 - 37.
AMA Polat A,ÖNDER M Duygudurum dengeleyicileri nedir?. 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi. 2003; 11(supp3): 21 - 37.
Vancouver Polat A,ÖNDER M Duygudurum dengeleyicileri nedir?. 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi. 2003; 11(supp3): 21 - 37.
IEEE Polat A,ÖNDER M "Duygudurum dengeleyicileri nedir?." 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi, 11, ss.21 - 37, 2003.
ISNAD Polat, Aslıhan - ÖNDER, M.Emin. "Duygudurum dengeleyicileri nedir?". 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi 11/supp3 (2003), 21-37.